Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center…
Read More